BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akiyama Y, Sasaki A, Endo F, Nikai H, Amano S, Umemura A, Baba S, Chiba T, Kimura T, Takahara T, Nitta H, Otsuka K, Mizuno M, Kimura Y, Koeda K, Iwaya T. Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis. World J Surg Oncol 2018;16:122. [PMID: 29966526 DOI: 10.1186/s12957-018-1420-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Muir D, Antonowicz S, Whiting J, Low D, Maynard N. Implementation of the Esophagectomy Complication Consensus Group definitions: the benefits of speaking the same language. Dis Esophagus 2022:doac022. [PMID: 35673848 DOI: 10.1093/dote/doac022] [Reference Citation Analysis]
2 Hou S, Pan Z, Hao X, Hang Q, Ding Y. Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer. Cancers (Basel) 2021;13:5162. [PMID: 34680311 DOI: 10.3390/cancers13205162] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Kobayashi K, Kanetaka K, Yoneda A, Kobayashi S, Maruya Y, Isagawa Y, Yoshimoto T, Migita K, Kawaguchi Y, Kuba S, Morita M, Okada S, Kosaka T, Yamaguchi S, Inoue Y, Adachi T, Hidaka M, Torashima Y, Ito S, Takatsuki M, Eguchi S. Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience. J Gastrointest Cancer 2021;52:582-92. [PMID: 32524305 DOI: 10.1007/s12029-020-00431-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]